Status:

NOT_YET_RECRUITING

INTACT Trial - an Observational Study to Assess Neuropathy in Diabetic Children

Lead Sponsor:

Heim Pal Children's Hospital

Conditions:

Diabetes Mellitus

Eligibility:

All Genders

5-18 years

Brief Summary

It is a prospective, cross-sectional, observational, controlled, single centre clinical study. Diabetic patients fulfilling the inclusion criteria and healthy controls will have uroflowmetry examinati...

Detailed Description

The autonomic nervous system function is examined by the reproducible and standardized cardiovascular reflex tests described by Ewing et al.. During the examination, electrocardiogram and blood pressu...

Eligibility Criteria

Inclusion

  • 5-18 years (boys, girls) with type 1, type 2 and monogenic DM

Exclusion

  • Acute febrile condition (≥38 °C core temperature) in the past seven days
  • Acute or chronical urinary tract or kidney disease: renal insufficiency (GFR ≤ 60 mL/min per 1.73 m2, urinary tract infection
  • Urological disease: bladder cancer, urolithiasis, urethral stricture, posterior urethral valve, meatal stenosis, previous genitourinary surgery, conditions causing urinary outflow problems (phimosis, hypospadias, vesicoureteral reflux)
  • Cystic fibrosis-related diabetes (CFRD)
  • Neurological disorders (multiple sclerosis, transient ischaemic attack, transverse myelitis, myelocele, meningomyelocele, previous spinal cord operation, or operation which might injure the sacral nerve plexus)
  • Medicines taken which can cause neuropathy:
  • Cytostatic agents: cyclophosphamide, platinum-based antineoplastic agents, vinca alkaloids, epothilones, taxanes, proteasome inhibitors, immunomodulatory drugs
  • Immunosuppressive agents: TNF-alfa inhibitors (adalimumab, infliximab, etanercept), interferon
  • Cardiovascular medicines: statins, digoxin, amiodaron
  • Antimicrobial agents: nitrofurantoin, linezolid, voriconazole, itraconazole, antituberculotics, metronidazole, fluoroquinolone
  • Anti-ulcerative agent: cimetidin
  • Neuropsychological agents: levodopa, fenitoin
  • Psychiatric disorders that prevents participation / collaboration in the study
  • Constipation (defined according to the Rome IV criteria)
  • Voided volume \<20 mL
  • Patients who are pregnant, or gave birth in the last 12 months
  • Lack of consent of the patient or legal representative; the patient or legal representative withdraws his or her voluntary consent during the study

Key Trial Info

Start Date :

September 1 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2027

Estimated Enrollment :

350 Patients enrolled

Trial Details

Trial ID

NCT05247840

Start Date

September 1 2022

End Date

September 1 2027

Last Update

August 5 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Heim Pal National Pediatric Institute

Budapest, Hungary, 1089